Publications by authors named "S Samoud"
The interplay between the cytokine network and antipsychotic treatment in schizophrenia remains poorly understood. This study aimed to investigate the impact of psychotropic medications on serum levels of IFN-γ, IL-4, TGF-β1, IL-17, and BAFF, and to explore their relationship with psychopathological features. We recruited 63 patients diagnosed with schizophrenia in the acute phase, all of whom were either drug-naïve or had been drug-free for at least three months.
View Article and Find Full Text PDFArticle Synopsis
- Schizophrenia (SZ) may have an autoimmune aspect, as indicated by higher levels of antiphospholipid antibodies in patients compared to healthy individuals.
- * The study analyzed serum samples from 80 drug-free SZ patients and 80 matched controls, finding significantly elevated aCL-IgM, aCL-IgA, and aβ2GPI-IgA levels in SZ patients.
- * These findings suggest a potential autoimmune link in SZ, warranting further research into the role of these antibodies in the disease's development and their connection to antiphospholipid syndrome.
Introduction: Post-COVID syndrome (PCS) is characterized by a polymorphism of symptoms with hypothetical pathophysiological mechanisms. Here, we aimed to analyze the profile of inflammatory cytokines in patients with PCS and to study the relationship between this profile, the clinical symptoms as well as the endothelial function in PCS.
Methods: Our analytical study involved all eligible patients (n = 66) with PCS included from April 2021 to December 2021.
Background: Allogeneic hematopoietic stem cell transplantation (ASCT) induces acquired immunodeficiency, potentially altering vaccine response. Herein, we aimed to explore the clinical tolerance and the humoral and cellular immune responses following anti-SARS-CoV-2 vaccination in ASCT recipients.
Methods: A prospective, non-randomized, controlled study that involved 43 ASCT subjects and 31 healthy controls.
(1) Background: This study aimed to compare the immunogenicity of the mix-and-match CoronaVac/BNT162b2 vaccination to the homologous CoronaVac/CoronaVac regimen. (2) Methods: We conducted a simple-blinded randomized superiority trial to measure SARS-CoV-2 neutralization antibodies and anti-spike receptor binding domain (RBD) IgG concentrations in blood samples of participants who had received the first dose of CoronaVac vaccine followed by a dose of BNT162b2 or CoronaVac vaccine. The primary endpoint for immunogenicity was the serum-neutralizing antibody level with a percentage of inhibition at 90% at 21-35 days after the boost.
View Article and Find Full Text PDF